Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGylated recombinant consensus interferon variant vs Pegasys in chronic hepatitis C
CTR20130081Phase 3Active
- Sponsor
- Chongqing Fujin Biopharmaceutical
- Start
- Feb 2014
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegylated recombinant consensus interferon variant in hepatitis C virus infection, sponsored by Chongqing Fujin Biopharmaceutical. Started Feb 2014; status: active.
02
Drugs
pegylated recombinant consensus interferon variant
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20130081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130081.